The CIPC or chlorpropham is used on potatoes as "sprouting inhibitor". These lasts years, some set of belgian potatoes treated by CIPC exceeded the Maximum Residue Limit (MRL), fixed at 5 mg/kg. The heterogeneity of sprout inhibitor application would be one of the causes of over-dosage. In order to estimate the distribution of CIPC between potatoes, according to the formulation used (DP, EC and HN), a research project financed by "le fond budgétaire des matières premieres" has been set up. In order to evaluate the distribution of CIPC into the pile of potatoes, the efficiency of the different formulations as well as the residues caused by their application on tubers, some tests have been placed in the storage hall. These tests consist in taking off some samples at different places into the pile of potatoes during storage and destocking. The content of CIPC is analysed by capillary gas chromatography with detection by mass spectrometry detection (GC-MS) or nitrogen specific detection (GC-NPD). To estimate the efficiency, the sprouting are observed every month and samples of potatoes are taken off on the top of the pile to control the evolution of CIPC content. Considering the results of the tests, the inhibitor treatment with the formulation DP+HN seems to be the more efficient. As for the residues, the formulation DP leads to a higher content of CIPC than HN, that has a very low concentration. After treatment, the quantity really applied on tubers depends on the formulation used. In fact, 50% of CIPC applied by DP formulation are found on tubers but hardly 10%, after gas application.
Download full-text PDF |
Source |
---|
Front Immunol
January 2025
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Muscle-invasive bladder cancer (MIBC) is a prevalent cancer characterized by molecular and clinical heterogeneity. Assessing the spatial heterogeneity of the MIBC microenvironment is crucial to understand its clinical significance.
Methods: In this study, we used imaging mass cytometry (IMC) to assess the spatial heterogeneity of MIBC microenvironment across 185 regions of interest in 40 tissue samples.
BJC Rep
November 2024
Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Background: Peritoneal metastasis, a major complication of colorectal cancer (CRC), often leads to poor quality of life and unfavorable outcomes. Despite numerous studies characterizing its biological features in CRC, intratumor heterogeneity and interactions between cancer cells and tumor microenvironment cells remain poorly understood.
Methods: To explore these aspects, we performed single-cell transcriptome analysis of matched primary tumor and peritoneal metastasis samples from a treatment-naïve patient.
Adv Sci (Weinh)
December 2024
Department of Geriatric Dentistry, Beijing Laboratory of Biomedical Materials, Peking University School and Hospital of Stomatology, Beijing, 100081, P. R. China.
Lab Chip
November 2024
Department of Biomedical Engineering, University of Delaware, Newark, DE 19713, USA.
The spatial organization of biophysical and biochemical cues in the extracellular matrix (ECM) in concert with reciprocal cell-cell signaling is vital to tissue patterning during development. However, elucidating the role an individual microenvironmental factor plays using existing models is difficult due to their inherent complexity. In this work, we have developed a microphysiological system to spatially pattern the biochemical, biophysical, and stromal cell composition of the ECM along an epithelialized 3D microchannel.
View Article and Find Full Text PDFMol Oncol
September 2024
Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC) have high tumor mutation burden and tumor immunogenicity, exhibiting a higher response rate to immunotherapy and better survival. However, a portion of MSI-H CRC patients still experience adverse disease outcomes. We aimed to identify the tumor-autonomous regulators determining these heterogeneous clinical outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!